Coronary stent restenosis in patients treated with cilostazol
about
An unusual case of acute respiratory failure in a patient with pulmonary veins stenosis late after catheter ablation of atrial fibrillation: a case report and the review of the literatureComparing the effectiveness and safety between triple antiplatelet therapy and dual antiplatelet therapy in type 2 diabetes mellitus patients after coronary stents implantation: a systematic review and meta-analysis of randomized controlled trialsAntiplatelet therapy for carotid artery stentingThe Many Faces of the A2b Adenosine Receptor in Cardiovascular and Metabolic DiseasesCilostazol activates function of bone marrow-derived endothelial progenitor cell for re-endothelialization in a carotid balloon injury modelEffect of pioglitazone on in-stent restenosis after coronary drug-eluting stent implantation: a meta-analysis of randomized controlled trialsClopidogrel desensitization: case report and review of published protocols.Triple antiplatelet therapy for preventing vascular events: a systematic review and meta-analysis.Open-Label Phase I Clinical Study to Assess the Safety and Efficacy of Cilostazol in Patients Undergoing Internal Carotid Artery Stent PlacementStudy design and rationale of 'Influence of Cilostazol-based triple anti-platelet therapy on ischemic complication after drug-eluting stent implantation (CILON-T)' study: A multicenter randomized trial evaluating the efficacy of Cilostazol on ischemAdvances in targeting cyclic nucleotide phosphodiesterasesCombination of cilostazol and clopidogrel attenuates rat critical limb ischemia.Efficacy and safety of adjunctive cilostazol to dual antiplatelet therapy after stent implantation: an updated meta-analysis of randomized controlled trials.Levels and values of lipoprotein-associated phospholipase A2, galectin-3, RhoA/ROCK, and endothelial progenitor cells in critical limb ischemia: pharmaco-therapeutic role of cilostazol and clopidogrel combination therapy.The association between progression of atherosclerosis and the methylated amino acids asymmetric dimethylarginine and trimethyllysine.Phosphodiesterases Regulate BAY 41-2272-Induced VASP Phosphorylation in Vascular Smooth Muscle Cells.Cilostazol, Not Aspirin, Prevents Stenosis of Bioresorbable Vascular Grafts in a Venous ModelInteraction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy AcAge, male gender, and atrial fibrillation predict lower extremity amputation or revascularization in patients with peripheral artery diseases: a population-based investigation.A review of antiplatelet drugs, coronary artery diseases and cardiopulmonary bypass.Restenosis related to percutaneous coronary intervention has been solved?Effects of cilostazol against the progression of carotid IMT in symptomatic ischemic stroke patientsCoping with new challenges in acute coronary syndromes.Cypher versus Taxus: the stent war.Cilostazol improves long-term patency after percutaneous transluminal angioplasty in hemodialysis patients with peripheral artery disease.Protective effects of cilostazol against transient focal cerebral ischemia and chronic cerebral hypoperfusion injury.Triple antiplatelet therapy vs. dual antiplatelet therapy in patients undergoing percutaneous coronary intervention: an evidence-based approach to answering a clinical query.Recurrent stroke: where do we stand with the secondary prevention of noncardioembolic ischaemic strokes?Efficacy of triple anti-platelet therapy including cilostazol in acute myocardial infarction patients undergoing drug-eluting stent implantation.Safety and efficacy of cilostazol in the management of intermittent claudication.Update on oral antiplatelet therapy: principles, problems and promises.Negative Association of Circulating MicroRNA-126 with High-sensitive C-reactive Protein and Vascular Cell Adhesion Molecule-1 in Patients with Coronary Artery Disease Following Percutaneous Coronary Intervention.Emerging drugs for coronary restenosis: the role of systemic oral agents the in stent era.Addition of cilostazol to aspirin and a thienopyridine for prevention of restenosis after coronary artery stenting: a meta-analysis.Pharmacological prevention and management of restenosis.Antithrombotic therapy in patients with diabetes mellitus and coronary artery disease.Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises.Cilostazol and atherogenic dyslipidemia: a clinically relevant effect?Antiplatelet therapy and vascular disease: an update.Clinical value of antiplatelet therapy in patients with acute coronary syndromes and in percutaneous coronary intervention.
P2860
Q26779375-C3589A22-3355-4E73-9C32-C72D991D4177Q26785723-21062DBD-5A9E-42A1-B8EB-E621A3720C99Q26852304-A3776725-22DB-4684-8295-63AA511EDF9FQ28080657-ADFA816B-35D9-4EEB-9D21-2470502C596BQ28477044-94C3A5D1-688B-4252-AC4C-A153AD4914B7Q28543544-6BA6596B-7215-4182-AA0F-8BAE301994D7Q33378440-6671D419-AE05-4CA3-9BF9-B7F9BA5339D2Q33390176-CB410816-E580-4F96-A588-EB7E12B3A191Q33781981-5A72B8B0-6035-47BA-B275-A92596C5CDC7Q34114530-981D6C58-258C-476D-BBAF-F6D0FD547B50Q34139490-520E5210-192F-4795-B624-81F301C34E61Q34381782-409972A7-BD2C-45F6-8789-7397C125A4B0Q34521985-CAF22656-A2FD-48A4-9991-1741162ABBA2Q34524341-94A46C40-9596-4869-AEFB-B0EB1A5AE5A4Q34755672-EF1EDCA9-1B3F-496E-BB61-0CC0D5904040Q35740400-6CA5C7B1-F2FC-4E67-A427-98DEEB4AB44FQ35993782-91C03BAB-3691-4F2B-BEB1-F4DE98BB8157Q36036395-7A2FE07A-431D-439D-B7CC-5EF36AE780B9Q36238939-1FEECCE5-BD70-4FD5-B2F2-F7F03B8AD013Q36374457-41932C80-2E9A-4E24-889C-F42B89B25A17Q36486769-C237561B-2485-425A-8B17-B7814A327776Q36503391-A4663A95-3C65-42F2-B076-4A6E9359CA57Q36575461-3F2D0AF9-4CFE-4FB0-A6C1-9E8E9C6221B7Q36654328-1834EC11-BB73-4C15-9AF9-3123E6E513C0Q36736604-34A8EBBB-89EE-4243-8D76-7B3B7AA7BF15Q37164669-F2D5CCDF-82D3-492B-8EA8-0D739FFF038DQ37321394-21854C44-2CAE-4D3A-B1FE-A7D53BA5CB9DQ37362773-C242DC0A-52FF-4BB1-8D07-AD7186085BC9Q37408663-0016C4A6-C79F-4AAB-9A30-3875826FCB55Q37428855-A1841689-441F-42EA-8EEC-FF238AE7B94EQ37486605-0DD02BD5-C307-4525-B80E-D9D12488C37CQ37487606-BB47211A-4AED-4AA0-9B3D-3359E1EF57C8Q37588002-072F7116-31F5-490A-8688-30D4C41581AFQ37676766-5D10CCDD-788D-4E86-9804-AFC5ABDAB30BQ37756979-AAE3920E-447C-4B15-B6A7-C6A8D3E7D4F8Q37797795-7D98FE5A-BFAB-471E-A9A2-9FD611FCE286Q37827882-C91AA06F-EFEE-4EDC-B132-B8AB927CB2B7Q37834033-A1A59876-64DD-41F6-BC5E-2391B28C7862Q37838100-214456C4-0CF1-467F-9136-00C1A7EE38A8Q37841560-FD549FE7-005F-4973-A914-837610E8CF41
P2860
Coronary stent restenosis in patients treated with cilostazol
description
2005 nî lūn-bûn
@nan
2005 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Coronary stent restenosis in patients treated with cilostazol
@ast
Coronary stent restenosis in patients treated with cilostazol
@en
Coronary stent restenosis in patients treated with cilostazol
@nl
type
label
Coronary stent restenosis in patients treated with cilostazol
@ast
Coronary stent restenosis in patients treated with cilostazol
@en
Coronary stent restenosis in patients treated with cilostazol
@nl
prefLabel
Coronary stent restenosis in patients treated with cilostazol
@ast
Coronary stent restenosis in patients treated with cilostazol
@en
Coronary stent restenosis in patients treated with cilostazol
@nl
P2093
P1433
P1476
Coronary stent restenosis in patients treated with cilostazol
@en
P2093
Cindy L Grines
Claudine Jurkovitz
David R Holmes
Dean J Kereiakes
Douglas C Morris
Elizabeth Block
G B John Mancini
Henry Liberman
John S Douglas
Jovonne Foster
P304
P356
10.1161/CIRCULATIONAHA.104.530097
P407
P577
2005-11-01T00:00:00Z